{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:59:50Z","timestamp":1792897190628,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"DOI":"10.1007\/s10006-025-01383-x","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:42:28Z","timestamp":1744764148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of MRONJ in patients treated with antiresorptive agents for glucocorticoid-induced osteoporosis"],"prefix":"10.1007","volume":"29","author":[{"given":"Hidenobu","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kanemaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nozawa-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaharu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","volume":"10","author":"S Timmermans","year":"2019","unstructured":"Timmermans S, Souffriau J, Libert C (2019) A general introduction to glucocorticoid biology. Front Immunol 10:1545. https:\/\/doi.org\/10.3389\/fimmu.2019.01545","journal-title":"Front Immunol"},{"issue":"4","key":"1383_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S et al (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese society for bone and mineral research: 2014 update. J Bone Min Metab 32(4):337\u2013350. https:\/\/doi.org\/10.1007\/s00774-014-0586-6","journal-title":"J Bone Min Metab"},{"issue":"4","key":"1383_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","volume":"15","author":"I Chiodini","year":"2020","unstructured":"Chiodini I, Falchetti A, Merlotti D, Eller Vainicher C, Gennari L (2020) Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Rev Endocrinol Metab 15(4):283\u2013298. https:\/\/doi.org\/10.1080\/17446651.2020.1772051","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"8","key":"1383_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437\u2013447. https:\/\/doi.org\/10.1038\/s41574-020-0341-0","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1383_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F (2022) Secondary osteoporosis. Endocr Rev 43(2):240\u2013313. https:\/\/doi.org\/10.1210\/endrev\/bnab028","journal-title":"Endocr Rev"},{"key":"1383_CR6","unstructured":"Committee for the Revision of Guidelines on the Management and Treatment of glucocorticoid-Induced Osteoporosis of the Japanese Society for Bone and Mineral Research: guidelines for the management of glucocorticoid-induced osteoporosis 2023 (2023) Nankodo"},{"key":"1383_CR7","doi-asserted-by":"publisher","unstructured":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines American College of Rheumatology Task Force on Osteoporosis Guidelines, Guidelines (1996) Arthritis Rheum 39(11):1791\u20131801. https:\/\/doi.org\/10.1002\/art.1780391104","DOI":"10.1002\/art.1780391104"},{"issue":"2","key":"1383_CR8","doi-asserted-by":"publisher","first-page":"e202202948","DOI":"10.5546\/aap.2022-02948.eng","volume":"122","author":"O Brunetto","year":"2024","unstructured":"Brunetto O, Cassinelli HR, Espada G et al (2024) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics. Arch Argent Pediatr 122(2):e202202948. https:\/\/doi.org\/10.5546\/aap.2022-02948.eng","journal-title":"Arch Argent Pediatr"},{"issue":"1","key":"1383_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H et al (2017) Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw. J Bone Min Metab 35(1):6\u201319. https:\/\/doi.org\/10.1007\/s00774-016-0810-7","journal-title":"J Bone Min Metab"},{"issue":"5","key":"1383_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg 80(5):920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"issue":"25","key":"1383_CR11","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE et al (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37(25):2270\u20132290. https:\/\/doi.org\/10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"issue":"2","key":"1383_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","volume":"20","author":"AK McDonough","year":"2008","unstructured":"McDonough AK, Curtis JR, Saag KG (2008) The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20(2):131\u2013137. https:\/\/doi.org\/10.1097\/BOR.0b013e3282f51031","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"1383_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40265-019-01145-6","volume":"79","author":"HG Raterman","year":"2019","unstructured":"Raterman HG, Bultink IEM, Lems WF (2019) Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 79(10):1065\u20131087. https:\/\/doi.org\/10.1007\/s40265-019-01145-6","journal-title":"Drugs"},{"issue":"6","key":"1383_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00774-021-01236-z","volume":"39","author":"S Soen","year":"2021","unstructured":"Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M (2021) Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Min Metab 39(6):1019\u20131030. https:\/\/doi.org\/10.1007\/s00774-021-01236-z","journal-title":"J Bone Min Metab"},{"issue":"12","key":"1383_CR15","doi-asserted-by":"publisher","first-page":"e0243851","DOI":"10.1371\/journal.pone.0243851","volume":"15","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang M, Shen Z, Ke J, Zhang D, Yin F (2020) Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials. PLoS ONE 15(12):e0243851. https:\/\/doi.org\/10.1371\/journal.pone.0243851","journal-title":"PLoS ONE"},{"issue":"2","key":"1383_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/rheumatology\/keaa228","volume":"60","author":"J Deng","year":"2021","unstructured":"Deng J, Silver Z, Huang E et al (2021) Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatol (Oxf Engl) 60(2):649\u2013657. https:\/\/doi.org\/10.1093\/rheumatology\/keaa228","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"3","key":"1383_CR17","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","volume":"40","author":"CL Liu","year":"2017","unstructured":"Liu CL, Lee HC, Chen CC, Cho DY (2017) Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med 40(3):E146\u2013E157. https:\/\/doi.org\/10.25011\/cim.v40i3.28394","journal-title":"Clin Invest Med"},{"issue":"1","key":"1383_CR18","doi-asserted-by":"publisher","first-page":"dgz023","DOI":"10.1210\/clinem\/dgz023","volume":"105","author":"L Ding","year":"2020","unstructured":"Ding L, Hu J, Wang D et al (2020) Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures. J Clin Endocrinol Metab 105(1):dgz023. https:\/\/doi.org\/10.1210\/clinem\/dgz023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1383_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00774-020-01171-5","volume":"39","author":"I Tanaka","year":"2021","unstructured":"Tanaka I, Tanaka Y, Soen S, Oshima H (2021) Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. J Bone Min Metab 39(3):446\u2013455. https:\/\/doi.org\/10.1007\/s00774-020-01171-5","journal-title":"J Bone Min Metab"},{"issue":"3","key":"1383_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/mr\/roab034","volume":"32","author":"I Tanaka","year":"2022","unstructured":"Tanaka I, Tanaka Y, Soen S, Oshima H (2022) Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. Mod Rheumatol 32(3):634\u2013640. https:\/\/doi.org\/10.1093\/mr\/roab034","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1383_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T et al (2015) Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos Int 26(2):765\u2013774. https:\/\/doi.org\/10.1007\/s00198-014-2964-2","journal-title":"Osteoporos Int"},{"issue":"10","key":"1383_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5794\/jjoms.67.571","volume":"67","author":"M Fujimori","year":"2021","unstructured":"Fujimori M, Toriyabe Y, Kaku N et al (2021) A multicenter prospective study on the incidence and cure of anti-resorptive agents-related osteonecrosis of the jaw: an epidemiological study in Eastern Hokkaido (in Japanese). Jpn J Oral Maxillofac Surg 67(10):571\u2013583. https:\/\/doi.org\/10.5794\/jjoms.67.571","journal-title":"Jpn J Oral Maxillofac Surg"},{"key":"1383_CR23","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Kishimoto H, Hagino H et al (2023) Antiresorptive agent-related osteonecrosis of the jaw: position paper. Japanese society of oral and maxillofacial surgeons, P 2023 of the Japanese allied committee on osteonecrosis of the jaw (in Japanese). https:\/\/www.jsoms.or.jp\/medical\/pdf\/work\/guideline_202307.pdf"},{"issue":"4","key":"1383_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T Yoneda","year":"2010","unstructured":"Yoneda T, Hagino H, Sugimoto T et al (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology and Japanese society of oral and maxillofacial surgeons. J Bone Min Metab 28(4):365\u2013383. https:\/\/doi.org\/10.1007\/s00774-010-0162-7","journal-title":"J Bone Min Metab"},{"issue":"6","key":"1383_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V et al (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 43(6):847\u2013854. https:\/\/doi.org\/10.1016\/j.jcms.2015.03.039","journal-title":"J Craniomaxillofac Surg"},{"issue":"7","key":"1383_CR26","doi-asserted-by":"publisher","first-page":"e0201343","DOI":"10.1371\/journal.pone.0201343","volume":"13","author":"S Soutome","year":"2018","unstructured":"Soutome S, Hayashida S, Funahara M et al (2018) Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS ONE 13(7):e0201343. https:\/\/doi.org\/10.1371\/journal.pone.0201343","journal-title":"PLoS ONE"},{"issue":"4","key":"1383_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis 24(4):527\u2013536. https:\/\/doi.org\/10.1111\/odi.12708","journal-title":"Oral Dis"},{"issue":"3","key":"1383_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.sdentj.2022.01.003","volume":"34","author":"R AlRowis","year":"2022","unstructured":"AlRowis R, Aldawood A, AlOtaibi M et al (2022) Medication-related osteonecrosis of the jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J 34(3):202\u2013210. https:\/\/doi.org\/10.1016\/j.sdentj.2022.01.003","journal-title":"Saudi Dent J"},{"issue":"5","key":"1383_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3803\/EnM.2021.1170","volume":"36","author":"HY Kim","year":"2021","unstructured":"Kim HY (2021) Review and update of the risk factors and prevention of antiresorptive-related osteonecrosis of the jaw. Endocrinol Metab (Seoul) 36(5):917\u2013927. https:\/\/doi.org\/10.3803\/EnM.2021.1170","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"6","key":"1383_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","volume":"126","author":"F Hallmer","year":"2018","unstructured":"Hallmer F, Andersson G, G\u00f6trick B, Warfvinge G, Anderud J, Bj\u00f8rnland T (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126(6):477\u2013485. https:\/\/doi.org\/10.1016\/j.oooo.2018.08.015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"1383_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.joms.2021.12.007","volume":"80","author":"M Ishimaru","year":"2022","unstructured":"Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H (2022) Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: A nationwide population-based study in Japan. J Oral Maxillofac Surg 80(4):714\u2013727. https:\/\/doi.org\/10.1016\/j.joms.2021.12.007","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"1383_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/odi.12632","volume":"23","author":"P Fung","year":"2017","unstructured":"Fung P, Bedogni G, Bedogni A et al (2017) Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis 23(4):477\u2013483. https:\/\/doi.org\/10.1111\/odi.12632","journal-title":"Oral Dis"},{"key":"1383_CR33","doi-asserted-by":"publisher","first-page":"774820","DOI":"10.3389\/fendo.2021.774820","volume":"12","author":"JH Park","year":"2021","unstructured":"Park JH, Kwoen MJ, Lee JR et al (2021) Gradual, but not sudden, dose-dependent increase of ONJ risk with bisphosphonate exposure: A nationwide cohort study in women with osteoporosis. Front Endocrinol (Lausanne) 12:774820. https:\/\/doi.org\/10.3389\/fendo.2021.774820","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1383_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","volume":"6","author":"HE Tamez-P\u00e9rez","year":"2015","unstructured":"Tamez-P\u00e9rez HE, Quintanilla-Flores DL, Rodr\u00edguez-Guti\u00e9rrez R, Gonz\u00e1lez-Gonz\u00e1lez JG, Tamez-Pe\u00f1a AL (2015) Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes 6(8):1073\u20131081. https:\/\/doi.org\/10.4239\/wjd.v6.i8.1073","journal-title":"World J Diabetes"},{"key":"1383_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","volume":"139","author":"A Bonaventura","year":"2018","unstructured":"Bonaventura A, Montecucco F (2018) Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 139:203\u2013220. https:\/\/doi.org\/10.1016\/j.diabres.2018.03.006","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-025-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-025-01383-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-025-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T02:12:10Z","timestamp":1765159930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-025-01383-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s10006-025-01383-x","relation":{},"ISSN":["1865-1569"],"issn-type":[{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Niigata University (approval no. 2020\u2009\u2212\u20090443). Since this is a retrospective study, we believe informed consent is unnecessary. However, since the patient\u2019s will should be respected when participating in the study, consideration was given to the patient by not only disclosing the information on the university\u2019s website \u201cNotice of Clinical Research\u201d but also by posting a notice about the study in the clinic room to disclose information about the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}